President, Merck Research Laboratories
Appears in 1 story
Overseeing Merck's post-Keytruda pipeline strategy
Cancer vaccines have promised to train the immune system against tumors for decades. None has delivered a durable, replicable benefit—until now. On January 20, 2026, Moderna and Merck reported that their personalized mRNA vaccine, combined with the immunotherapy Keytruda, cut the risk of melanoma recurrence or death by 49% at five years in a Phase 2b trial of 157 patients. The sustained result—identical to the three-year mark—suggests the vaccine permanently reprograms immune surveillance rather than offering temporary protection.
Updated Jan 25
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
